Who
Steve O'Loughlin
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, CNS Pharmaceuticals; Chief Financial Officer, Actinium Pharmaceuticals, Inc. (Delaware).
In numbers
- Trades disclosed
- 23
- Buys
- 3
- Sells
- 0
- Bought
- $14K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Jun 2017
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | CNSP CNS Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CNSP CNS Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —1,666 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —3,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —8,833 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —13,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —59,066 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —107,463 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —256,438 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —253,123 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —253,123 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —256,438 at $0.00 | filing |
| 1 Sep 2021filed 3 Sep 2021 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —107,463 at $0.00 | filing |
| 12 Aug 2020filed 14 Aug 2020 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —59,066 at $0.00 | filing |
| 12 Jul 2019filed 16 Jul 2019 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | $92K400,000 at $0.23 | filing |
| 10 Dec 2018filed 10 Dec 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Bought | $4,40010,000 at $0.44 | filing |
| 13 Jul 2018filed 17 Jul 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | $207K265,000 at $0.78 | filing |
| 15 Jun 2018filed 15 Jun 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Bought | $6,00012,000 at $0.50 | filing |
| 6 Mar 2018filed 8 Mar 2018 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code J | $5,00010,000 at $0.50 | filing |
News
No headline names them, or the companies they trade most, lately.